BioSpace News Archive

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), today announced that it has entered into securities purchase agreements with certain institutional and other accredited investors to raise $8.0 million through the issuance of 5,579,776 its ordinary shares and warrants to purchase up to 4,184,832 ordinary shares, at a purchase price of $1.43375 per share and associated warrant, in a private

With the majority of physicians now attending professional conferences virtually, new insights show that nearly half would like to see more of the core elements that make a conference engaging and memorable

COVID-19 survivors may be at risk for persistent complications, a condition referred to as Long COVID or Long Haul COVID LYT-100, an anti-fibrotic and anti-inflammatory agent, holds potential for treating inflammation and fibrosis implicated in a range of respiratory conditions, including those associated with COVID-19

New data from the DESTINY-Breast01 trial reinforce the efficacy of ENHERTU ® in HER2-positive metastatic breast cancer New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31 st International Symposium on ALS/MND taking place online from December 9 – December 11, 2020. Title: A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS): COURAGE-ALS Trial Design Session: Live

Inspira Technologies Ltd., an innovative medical technology company, announced today that it filed a patent application with the United States Patent and Trademark Office (USPTO) for its new blood oxygenation system, the AXT, which eliminates the need for invasive mechanical ventilation.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that it has secured an exclusive, worldwide license from EyeCRO LLC for its Microemulsion Drug Ocular Penetration System

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced updated timing of the balstilimab BLA filing to meet the FDA feedback to follow all patients for a median of 12 months and responders for a minimum of 6 months

RLS-0071 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease

New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degeneration I n the experimental allergic uveitis (EAU) disease model nomacopan reduce d Th17 effector T cell and macrophage activity in addition to known downregulation of neutrophils Long-acting forms of nomacopan were at least as effective in downregulating disease in EAU model as standard of care dexamethasone, which is associated with steroid related side effects